Table 3.
Adverse events in the two groups
| Event | IC* (n = 98) | IC + immunotherapy (n = 65) | p# | ||
|---|---|---|---|---|---|
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | ||
| Anorexia | 57 (58.2%) | 0 | 40 (61.5%) | 0 | |
| Nausea | 40 (40.8%) | 0 | 24 (36.9%) | 0 | |
| Fatigue | 30 (30.6%) | 0 | 23 (35.4%) | 0 | |
| Constipation | 25 (25.5%) | 0 | 18 (27.7%) | 0 | |
| Stomatitis | 17 (17.3%) | 0 | 17 (26.2%) | 0 | |
| Diarrhea | 15 (15.3%) | 0 | 13 (20.0%) | 0 | |
| Neutropenia | 12 (12.2%) | 10 (10.2%) | 10 (15.4%) | 4 (6.2%) | |
| Thrombocytopenia | 11 (11.2%) | 6 (6.1%) | 10 (15.4%) | 4 (6.2%) | |
| Vomiting | 8 (8.2%) | 0 | 6 (9.2%) | 0 | |
| Peripheral neuropathy | 7 (7.1%) | 0 | 6 (9.2%) | 0 | |
| Liver dysfunction | 7 (7.1%) | 0 | 6 (9.2%) | 0 | |
| Hypothyroidism | 7 (7.1%) | 0 | 6 (9.2%) | 0 | |
| Venous thrombosis | 2 (2.0%) | 2 (2.0%) | 2 (3.1%) | 2 (3.1%) | |
| Dizziness | 2 (2.0%) | 0 | 2 (3.1%) | 0 | |
| Cough | 1 (1.0%) | 0 | 0 | 0 | 0.596 |
* IC induction chemotherapy
#: the p value indicated the difference of the events of grade 3–4 between the two groups